Dr. Ning Ren 任宁
Chief Physician
Department of Hepatobiliary Oncology and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Prevention, early diagnosis, and treatment of liver cancer. Prevention of postoperative recurrence and comprehensive management of liver cancer.
Dr. Ren is a Chief Physician and doctoral supervisor at Zhongshan Hospital, Fudan University. Dr. Ren graduated from Shanghai Medical University in 1995 and has worked in the Liver Tumor Surgery Department since. Dr. Ren earned a master's degree in 2000 under Professor Wu Zhiquan and a doctorate in 2004 under Academician Tang Zhaoyou. In 2008, Dr. Ren was a visiting scholar in the Department of Surgery at the University of Hong Kong.
Name order: in Chinese the family name comes first (Ren Ning). Papers usually list the name as Ning Ren or Ren N.
Selected publications
101 papers on PubMed matched by name and affiliation; 25 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncologist, 2024 (senior author): FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma. PubMed 38986528
- Int J Gen Med, 2024 (senior author): The Prognostic Significance of CTSV Expression in Patients with Hepatocellular Carcinoma. PubMed 39465186
- Cancer Lett, 2024 (senior author): A novel protein encoded by circFOXP1 enhances ferroptosis and inhibits tumor recurrence in intrahepatic cholangiocarcinoma. PubMed 38945202
- Cancer Res, 2024 (senior author): Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy. PubMed 38484085
- Hepatol Int, 2023 (senior author): Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA. PubMed 37217808
- J Immunother Cancer, 2023 (senior author): Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma. PubMed 37385725
- Gastroenterology, 2023 (senior author): Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma. PubMed 36863689
- J Clin Transl Hepatol, 2022 (senior author): A Novel mRNA Signature Related to Immunity to Predict Survival and Immunotherapy Response in Hepatocellular Carcinoma. PubMed 36304510
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion